Syncona Ltd has taken the lead in financing a new cell therapy company that is developing induced pluripotent stem cell (iPSC) derived medicines. Clade Therapeutics, located in Cambridge, US, has a platform technology that ‘cloaks’ human pluripotent stem cells and their adult derivatives enabling the development of immune compatible cell transplantation therapies. The company is initially focused on demonstrating the potential of cloaked immune cells as cancer treatments.
